ArticleTherapeutic advances in hematology2025

Integrated Immune Landscape Analysis of RNA Splicing Factor-Mutant AML and Higher risk MDS Treated with Azacitidine ± Durvalumab.

Jan Philipp Bewersdorf et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.